<?xml version='1.0' encoding='UTF-8'?><xml><records><record><source-app name="HighWire" version="7.x">Drupal-HighWire</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Buckley, Rita</style></author></authors><secondary-authors><author><style face="normal" font="default" size="100%">Casella, Samuel J.</style></author></secondary-authors></contributors><titles><title><style face="normal" font="default" size="100%">Recognition and Management of Atypical Forms of Diabetes</style></title><secondary-title><style face="normal" font="default" size="100%">MD Conference Express</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2011</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2011-08-01 00:00:00</style></date></pub-dates></dates><pages><style  face="normal" font="default" size="100%">31-31</style></pages><abstract><style  face="normal" font="default" size="100%">Cystic fibrosis-related diabetes (CFRD) has increased in concert with gains in long-term survival of cystic fibrosis patients, with rates as high as 40% to 50% in adult cohorts. CFRD has many features of type 1 diabetes mellitus. The multicenter Cystic Fibrosis-Related Diabetes Therapy Trial recently confirmed that insulin therapy is beneficial in CFRD patients, safely reversing chronic weight loss even before the development of fasting hyperglycemia [Moran A et al. Diabetes Care 2009].</style></abstract><number><style face="normal" font="default" size="100%">5</style></number><volume><style face="normal" font="default" size="100%">11</style></volume></record></records></xml>